

Iperion Limited

Annual Meeting
30 September 2026



Agenda

- Welcome and Introductions
- Formalities
- Presentation to Shareholders
- Q&A Discussion
- Resolutions
- Appendix: Additional information on Pathoglaze

Formalities

- Attendance of the virtual meeting has been left open for all interested to be able to attend.
- The meeting is recorded.
- To ensure that voting is accounted for correctly, all votes will be required to be submitted electronically. For shareholders who have not voted yet via MUFG, but still wish to do so after the meeting, please forward your completed voting form to john.cilliers@iperion.co.nz by no later than 4pm today.
(contact John if you need a form)

Review of the year ended 31 March 2026

- No interest income in 2026 as cash was not placed in term deposits so as to be available to cover costs for an anticipated sales order.
- Fixed outsource manufacturing plant fee fully discounted for 2026.
- Admin expenses lower in 2026 with savings made in travel costs and audit fees. Savings were partially offset by increase in stock exchange fees.
- Impairment expense was on trademark intangibles. There were no costs for trademarks in 2026.
- There were no changes in the number of shares on issue.

	2026 \$	2025 \$
Interest income	10	20,382
Outsource Manufacturing Plant	0	150,000
Administrative expenses	294,605	317,781
Impairment expense	0	8,284
Net loss	294,595	455,683
Net assets	53,803	348,398
Cash and Term deposits	155,492	425,341

Cash Reserves and Financial Support

- Financial support:
 - The Company entered into a **loan agreement** with Elitesoft Asia, a company related to Mr Chang Ku EE, the majority shareholder and a director of the Company, pursuant to which Elitesoft provides a loan facility of \$250,000 to the Company at 8% interest (Hong Kong Monetary Authority Base Rate + 4%), which can be increased to US\$1,000,000 subject to approval by Iperion's shareholders.
 - Mr EE confirmed that he will provide financial support to the Company, if required to meet its working capital obligations and liabilities as they fall due, for at least a period of 12 months from the date of approval of the Company's financial statements (30 Jun 2026).
- Initiatives to conserve cash reserves:
 - Since January 2026, payment on 50% of directors' fees and 33% of the management fee are being deferred, until sufficient sales are achieved to move the company to a positive cash flow position.

Manufacturing Facilities

- Outsource Manufacturing Plant:
 - The fixed annual fee on the Pathoglaze outsource manufacturing plant fees for the financial year to March 2026 was fully discounted by the vendor and will be fully discounted through to March 2028.
 - The vendor is in the process of moving the manufacturing plant from Malaysia to Singapore. The equipment is currently in storage. Sufficient Pathoglaze compound has already been manufactured and is available to fill sales orders until the plant is setup again. In the interim, ongoing product development is being supported from the Licensor's facilities in Singapore where smaller product batches can also be manufactured if needed.
 - In recognition of the collaborative efforts undertaken between the inventor of Pathoglaze and Iperion, agreement was reached to permanently waive the customer and revenue performance targets under Iperion's exclusive world-wide license.

Progress and current activities

- Work undertaken during the year ending March 2026 mainly focused on completing the development of Pathoglaze infused polymer jute bags used for shipping cocoa and coffee beans. This work was being undertaken in collaboration with a multinational chocolate manufacturer
- Product tests and trials for specific applications continue with potential customers as they arise.
- With support from Mr EE, directors have also been investigating a range of alternative product and sales opportunities for the company.

Questions



Resolution 1

John Cilliers retires by rotation in accordance with the Company's constitution and NZX Listing Rule 2.7.1. Being eligible, John offers himself for re-election. The Board considers John to be an Independent Director. Accordingly, the shareholders of the Company are requested to consider and, if thought fit, pass the following resolution as an Ordinary Resolution.

Ordinary Resolution: That that John Cilliers, who retires in accordance with NZX Listing Rule 2.7.1, and being eligible for re-election, be re-elected as a director of IPR.

Proxies:

	For	Open	Against	% of Issued Capital	Abstain
Votes	406,661,251	4,000	9,000	78.98%	0
Holders	3	4	1		
Percentage	100.00%	0.00%	0.00%		

Resolution 2

Kuan Chong Ng (“KC”), retires by rotation in accordance with the Company’s constitution. Being eligible, KC offers himself for re-election at the Annual Meeting. The Board does not consider Mr Ng to be an Independent Director. Accordingly, the shareholders of the Company are requested to consider and, if thought fit, pass the following resolution as an Ordinary Resolution.

Ordinary Resolution: That Kuan Chong Ng, who retires in accordance with NZX Listing Rule 2.7.1, and being eligible for re-election, be re-elected as a director of IPR.

Proxies:

	For	Open	Against	% of Issued Capital	Abstain
Votes	406,661,251	4,000	9,000	78.98%	0
Holders	3	4	1		
Percentage	100.00%	0.00%	0.00%		

Resolution 3

BDO is automatically reappointed at the annual meeting as the auditor of the Company under section 207T of the Companies Act. This resolution authorises the Board to fix the fees and expenses of the auditor.

Ordinary Resolution: That the Board is authorised to fix BDO Auckland's fees and expenses as the auditor of IPR.

Proxies:

	For	Open	Against	% of Issued Capital	Abstain
Votes	8,141,908	4,000	0	1.58%	398,528,343
Holders	3	4	0		
Percentage	99.95%	0.05%	0.00%		

Thank you





Pathoglaze is a durable, high potency, anti-microbial product capable of being incorporated into raw materials for other products at the point of manufacture.

For example it can be incorporated in plastics masterbatch powders prior to product moulding or it can be applied to existing products as a thin film coating.



- Pathoglaze infused polymer jute bags used for shipping cocoa and coffee beans.
- These bags reduce losses that result from microbial contamination during shipping and transport.





Fine Powder (Additives)


- ✓ **PATHOGLAZE® Hyperion** is a high-potency **zinc-based** antimicrobial additive.
- ✓ Having a **core shell- nanopillar morphological structure**.
- ✓ It can kill, reduce and prevent the growth of harmful microorganism (e.g.: *bacteria*, *virus*, *fungi*, *algae*).
- ✓ Having an antimicrobial activity up to **99.9 % (test method: ISO22196)**.
- ✓ Can be **seamlessly incorporated** in a wide range of end-use products during the manufacturing process without interfering with the actual manufacturing setup.




HYPERION Additive
– greyish powder



Key Features



Area of Application



PLASTICS AND POLYMERS (Food-grade and non food-grade)

List of polymers compatible with PATHOGLAZE:

- i. Commodity thermoplastics (*i.e.*: PE, PS)
- ii. Engineering thermoplastics (*i.e.*: PC, ABS, PC/ABS, PA)
- iii. Thermosets (*i.e.*: epoxy)
- iv. Synthetic rubber (*i.e.*: NBR and EPDM)

PAINTS AND COATINGS



Polymer compound

- ✓ Our **PATHOGLAZE®** additives are compatible with almost all plastics and polymer materials (*i.e.: trial for PP, PC and ABS*).
- ✓ With **0.5%** of PATHOGLAZE loading = **99.9%** of antimicrobial activity (ISO22196)
- ✓ Seamlessly compound in polymer using the existing process
- ✓ Embedded within the polymer compound itself, delivering continuous protection against microbes without affecting gloss or matte surfaces, color, durability, and properties.

In-polymer Food Contact Test according to


- **US FDA 21 CFR 177.1520**

Migration Test according to Commission Regulation (EU)

- **EU 10/2011 Article 3 of European Regulation 1935/2004***

PASS

PASS



**PP compound with 0.5% of
PATHOGLAZE**



Potential
PATHOGLAZE
APPLICATION



Housewares:

Cutting boards, wall coverings, appliances,
toilet seats, flooring, mattresses



Commercial:

PVC blinds, car interiors, packaging, signs,
electronics, seating



Fitness:

yoga mats, footwear, duffle bags,
sports equipment



Construction materials:

flooring, vinyl siding, windows, insulation,
piping, roofing membranes



Healthcare:

business supplies, medical devices, seating,
countertops, storage



Antimicrobial Packaging (primary & secondary)

- i. Prevents the growth of bacteria and fungi on the surface.
- ii. Reduces bacteria in the surrounding area, and reduces the spread of infection.
- iii. Prolongs food shelf life.
- iv. Promotes product reusability and recyclability.





Thin Film

- ✓ **Thin film** is a **layer of material** with a thickness ranging from a nanometer to micrometer on the surface of a substrate.
- ✓ Harnessing the potential of zinc, PATHOGLAZE thin film is a **zinc-based thin-film** coating.
- ✓ **PATHOGLAZE® thin film** series is particularly targeted for coating on non-porous surfaces *i.e.*; **glass windows, solar panels, touch-sensitive displays, etc.** where transparency coating is a key consideration.

